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Abstract: Background: A number of studies have examined beliefs about medicines reuse. Although
the practice is prohibited in UK community pharmacy, it does take place elsewhere in the world
where it relies on visual checks of returned medicines as an indicator of their quality. One proposal
is to integrate sensor technology onto medication packaging as a marker of their quality instead.
Our aim was to gauge people’s beliefs about medicines reuse, in an experiment, with or without
sensor technology and with or without the promise of visual checks completed by a pharmacist,
as experimental conditions, should the practice be sanctioned in the UK in the future. Methods: A
between participant study was designed with two independent factors testing the hypothesis that
sensors and visual checks would increase pro-medicines-reuse beliefs. A questionnaire was used to
measure medicines reuse beliefs and collect qualitative comments. Results: Eighty-one participants
took part. Attitudes toward medication offered for reuse, participants’ perceived social pressure
to accept the medication, and their intention to take part in medicines reuse all increased with the
presence of sensors on packaging and with the promise of pharmacist visual checking, with the
former causing a greater increase than the latter, and the combination of both making the greatest
increase. People’s qualitative comments explained their concerns about medicines reuse, validating
the findings. The use of sensors on medication packaging warrants further investigation if regulators
are to consider approving medicines reuse in the UK.
Keywords: medicines; sensors; pharmacist; medicines reuse; attitudes
1. Introduction
A number of studies have examined people’s views about the idea of medicines reuse,
a practice that involves re-dispensing quality-checked, unused, prescribed medication
for other patients instead of disposal as waste [1–4]. This is important because a strong
body of evidence shows that inappropriate disposal of unwanted medicines (e.g., disposal
via domestic waste and the sewage system), in a host of countries, contributes to the
contamination of soil and groundwater with a multitude of drug substances which can
even make their way into drinking water [5,6]. Medicines reuse offers a potential solution
to minimizing this problem, by encouraging people to return their unwanted medicines to
the pharmacy, either for safe disposal or for re-dispensing to other patients [3]. Of course,
there are other much more significant ways of reducing environmental contamination
from medicinal products, including better research and manufacturing processes at the
pharmaceutical industry level, and more responsible prescribing and dispensing practices
within the community level [5]. However, medicines reuse, by encouraging people to
return their medicines to the pharmacy, also has the potential to help reduce the stockpiling
of medicines within patients’ homes, something that can otherwise lead to accidental poi-
soning and inappropriate self-administration of medicines for undiagnosed conditions [7].
It is also important to remember the financial impact of medication waste, considered
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in detail elsewhere [8,9]. Finally, there is the potential for medicines reuse to help with
the supply of medicines under special circumstances, for example when there are drug
shortages or affordability gaps.
Indeed medicines reuse is permitted in some countries such as Greece [10] and the
United States [11], mainly for benevolent reasons—the idea being, briefly, that suitable
medicines can re-enter the supply chain and be reissued to others in need. However,
medicines reuse is prohibited in the UK. The same is true for most other European counties
too. A snapshot report on the fate of unused pharmaceuticals in a number of European
countries, published in 2013 pointed to a promising recycling scheme in Hungary named
Recyclomed [12]. However, on inquiring about the scheme the authors of this paper were
recently informed, via email, that for drug safety reasons drug manufacturers opposed
both the reuse of medicines as well as any recycling of the packaging via that scheme.
Thus, in Hungary, the UK and most other countries in Europe, the main intervention for
addressing the inappropriate disposal of unwanted medicines is to offer formal waste
collection services for the sole purpose of incineration [12]. The exception is a scheme
offered in Portugal named Valormed, which although does not support medicines reuse,
does separate collections into elements to be incinerated and packaging components to be
recycled [12].
UK officials often cite uncertainties about the quality, safety and efficacy of returned
medicines kept in patients’ homes, outside of the formal supply chain, as the reason to
oppose the practice of medicines reuse [13–15]. These risks are also recognized by members
of the public who would not want to receive poor-quality, harmful or incorrect medication
as a result of medicines reuse [3]. Thus, the re-use or recycling of another patient’s medicine
is not normally recommended by the UK’s Department of Health and Social Care (DHSC).
This stance also has to be viewed within the context of a reliable, national healthcare service
that has no cause to risk compromising patient safety, theoretically or materially, for any
potential benefit that might be gained from sanctioning medicines reuse. However, as we
have argued elsewhere, a persistent objection to the idea of medicines reuse is unrealistic
because unpredictable events such as pandemics [16] and drug shortages [17] result in
temporary U-turns in the UK Government’s position on medicines reuse in any case,
but in a space devoid of sufficient investment and research. Thus, a reasonable stance
might be to recognize the risks associated with medicines reuse and try to ameliorate
these with potential solutions. To this end, we propose a robust mechanism for validating
the quality and safety of medicines kept within and outside of the formal supply chain,
using the novel ReMINDS (www.reading.ac.uk/ReMINDS, Accessed on 17 July 2021)
ecosystem. This system relies on active sensing technologies integrated with the Internet
of Things platform to indicate the ‘reusability’ of medicines while interconnecting the
relevant stakeholders [18,19]. The availability of such a system should make medicines
reuse, whether a temporary measure or not, a much safer practice in the future. Regardless,
engaging people in medicines reuse, should the practice be sanctioned by medicines
regulators in the future, will still rely on their voluntary participation in such a scheme.
For example, the recent proposal to permit care homes and hospices in the UK to draw
up standard operating procedures to enable medicines reuse if impacted by shortages
due to the pandemic, still required active consent from people affected by such a scheme
(donating and receiving) [20].
The studies that have examined people’s views about medicines reuse in countries such
as the UK and the Netherlands are clear that the practice would be acceptable to many people
provided the quality and safety of the medicines can be guaranteed [1–4]. For example, in the
Netherlands, 61.2% of survey respondents were willing to use medication returned unused
to the pharmacy by another patient as long as the quality of these medicines was somehow
verified [1]. In the UK too, we found 54.5% of our respondents intended to, wanted to (56.5%)
or expected to (56.5%) reuse medication in the future [4]. What-is-more, the findings from our
theory-driven study [21] highlight the importance of creating conditions that will illustrate to
people that medicines reuse would not expose them to additional medication-related risks [4].
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The current way in which returned medicines are screened for reuse relies on the judgement
of the pharmacist [22] or another registered health professional [20]. However, as we have
argued elsewhere, these methods currently only use history-checking and visual checks, and
do not uncover the actual prior storage conditions of returned medicines nor the impact of
that storage on the contents within—thus act as proxy measures of quality only. The gap in
the market, in our view, is for technologies, for example sensors to measure and track the
interaction of the storage conditions (e.g., temperature, light, humidity) with the medicinal
pack when kept outside of the formal pharmacy supply chain [18,19]. Sensors that work in
this way could reassure people, and reasonably regulators, about the continued quality of
reused medicines. Indeed, this is the basis of our proposed ReMINDS ecosystem.
To test these ideas with the public, whose participation in medicines reuse would
be key to its success in a hypothesized future scenario, we designed a simple two-factor
experiment to gauge people’s responses to the idea of medicines reuse, with or without
the presence of a sensor to monitor storage conditions and with or without assurances
about a pharmacist’s involvement in visual checking the candidate medicine. We imagined
that participants would view medicines reuse more favourably with the presence of a
sensor and if given specific information about a candidate medicines having been visually
checked by a pharmacist.
2. Materials and Methods
2.1. Design
A between-participants design was used. One independent variable was the presence
of a sensor on the medication box (we chose a standard levothyroxine calendar pack) to
monitor the storage environment of the medication presented to the participants. This had
two conditions, one condition where the packaging was presented without the sensor and
one where it was shown with the sensor accompanied by the researcher reading out the
following script: “There is a sensor monitoring the storage conditions of this medication
box. This means the temperature and humidity is monitored.” The other independent
variable was visual checking. This also consisted of two conditions, one condition where no
additional information on visual checking was given and one where additional information
was provided, that a pharmacist had been involved in visual checking the medicine, with
the following script read out: “The pharmacist has performed quality and safety checks
before giving this medication to you”. The combination of the different conditions is shown
in Table 1.
Table 1. The experimental combinations.
Experiment Sensor on Packaging Pharmacist Visual Check
Scenario 1 No No
Scenario 2 Yes No
Scenario 3 No Yes
Scenario 4 Yes Yes
The dependent variable was medicines reuse beliefs. This was measured by asking
the participants to complete a short questionnaire after being shown the medication box
for their specific scenario.
To control for any differences in the participants, the scenarios were allocated at ran-
dom. In addition, some basic demographic data about the participants were collected in
order to check for any substantial differences in the four groups. To control for potential
experimenter effects, the researcher was careful to give the experimental instructions in a
standard way each time, not favouring a certain outcome, nor giving away any verbal/non-
verbal cues that would unduly influence the participants. To control for any other differ-
ences in the way the medication was perceived, the boxes of levothyroxine tablets presented
were totally identical (apart from the presence of the sensor where appropriate).
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2.2. Hypothesis
Our hypothesis was that participants would give more positive responses to questions
about medicines reuse with the presence of the sensor on the packaging compared to
without. We also tested another hypothesis that the addition of a statement about the
pharmacist’s involvement in the visual checking of the medication would also result in
more positive responses to questions about medicines reuse compared to without.
2.3. Materials
Two identical calendar packs of levothyroxine 100 mcg tablets, which usually requires
storage at room temperature, were used to represent the medication under consideration.
The box containing the ‘sensor’ (used in Experiments 2 and 4) was fitted with a temperature
indicator which was a Timestrip® Plus sticker (Figure 1) and a photo-reduced version of
an SCS humidity indicator (available from https://staticcontrol.descoindustries.com/
Accessed on 17 July 2021). Both indicators were non-functioning and used for theoretical
purposes in order to simulate the monitoring of temperature and humidity, respectively,
via a sensor.
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Figure 2. The theory of pla ned behavior model a plied to reusing medication.
The questionnaire composed of thre sections. Section 1 consisted of demographic
questions on gender, age, level of education and ethnicity. Section 2 listed 1 statements,
each with a five-point Likert response scale to indicate agre ment/disagre ment with the
statements, fr tr l isagree to strongly agr e. The statements were categorised
into three clusters: (a) attitude toward reusing the medicine; (b) normative beliefs/social
pressure to accept the medication for reuse; (c) intention to accept the medication (see
Table 2). A third section invited the participants to add any comments by hand.
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Table 2. The 11 statements categorized according to the theory of planned behaviour (TPB) model.
For the analysis, the mean score for ‘attitude’ for each individual was calculated from responses to
Questions 1–5, for ‘normative beliefs/social pressure’ from Questions 6–9, and for ‘intention’ from
Questions 10 and 11.
TPB Category Statement
Attitude toward reusing the medication
1. This medication would be safe to use
2. This medication would be harmful
3. This medication would be of low quality
4. This medication would be good
5. It would be satisfying to accept this
medication
Normative beliefs/social pressure to accept the
medication for reuse
6. My family would believe I should accept
this medication
7. My close friends would believe I should
accept this medication
8. My doctor would believe that I should
accept this medication
9. My pharmacist would believe that I should
accept this medication
Intention to accept the medication 10. I would accept this medication11. I would want to use this medication
2.4. Procedure
Participants from the University of Reading’s Whiteknights Campus were approached
and consented via an information leaflet. Each participant was shown a standard empty
levothyroxine medication box and allocated at random to receive one of four scenarios
all with the same information about medicines reuse; with or without the presence of the
sensor, and with or without the visual-check information involving the pharmacist (see
Table 1). At the experiment’s start, a standard script was followed for all of the participants:
“This research project is about re-using medicines, which is when a pharmacist gives
medication that has been brought back to their pharmacy by one patient, for another
patient to use. Currently, in the UK this is not allowed. Imagine you need to collect
some medication for yourself from the pharmacy. You are told that the pharmacist had
previously given this particular box of medication to another patient (shows participants
the medication box, according to scenario and reads out the additional information for
Scenarios 2, 3, and 4 as appropriate). That patient did not need this box of medication,
so they returned it to the pharmacy a month later. The box is unopened, is the original
packaging and the anti-tampering sticker is still attached to it. The medication is also well
within the expiry date. This box of medication is then given to you for your own use. Do
you have any questions so far? Based on this information, please fill out the questionnaire.”
All participants then completed the questionnaire. The participants were finally
debriefed about the aims of the study and asked if they had any questions.
Data from questionnaires were transferred to SPSS® (version 25). The scores from
the negatively phrased statements (2, 3) were reversed. The data were then analysed
using analysis of variance (ANOVA) with the mean attitude toward the medication, mean
perceived social pressure (normative beliefs) to accept the medication, and mean intention
to accept the medication, as the dependent variables. The presence of the sensor and
inclusion of pharmacist visual-check information were the independent variables.
2.5. Participants
Eighty-one participants took part in this experiment. Participants were either staff or
students present on the Whiteknights Campus of the University of Reading in November or
December 2019. They were approached opportunistically and recruited with an information
letter and consent form. There were 41 females, 39 males and 1 who preferred not to disclose
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their gender. The participants were aged between 18 and 64. There was an even distribution
of gender, age, educational qualification and ethnicity across the different experimental
scenarios as shown in Table 3.
Table 3. The socio-demographic information of the participants according to the experimental scenarios.
Characteristics Scenario 1(n = 20) (%)
Scenario 2
(n = 20) (%)
Scenario 3
(n = 21) (%)
Scenario 4
(n = 20) (%)
Total
(n = 81) (%)
Gender
Female 11 (55.0) 10 (50.0) 12 (57.0) 8 (40.0) 41 (50.6)
Male 9 (45.0) 10 (50.0) 8 (38.0) 12 (60.0) 39 (48.1)
Prefer not to say 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 1 (1.2)
Age
18–24 12 (60.0) 7 (35.0) 11 (52.0) 9 (45.0) 39 (48.1)
25–34 4 (20.0) 9 (45.0) 5 (24.0) 4 (20.0) 22 (27.2)
35–44 2 (10.0) 1 (5.0) 1 (5.0) 5 (25.0) 9 (11.1)
45–54 1 (5.0) 1 (5.0) 3 (14.0) 1 (5.0) 6 (7.4)
55–64 1 (5.0) 2 (10.0) 1 (5.0) 1 (5.0) 5 (6.2)
Highest qualification
GCSE 1 (5.0) 3 (15.0) 4 (19.0) 4 (20.0) 12 (14.8)
A level 8 (40.0) 3 (15.0) 4 (19.0) 7 (35.0) 22 (27.2)
Bachelor’s degree 7 (35.0) 7 (35.0) 7 (33.0) 4 (20.0) 25 (30.9)
Master’s degree 3 (15.0) 2 (10.0) 4 (19.0) 2 (10.0) 11 (13.6)
PhD 1 (5.0) 0 (0.0) 0 (0.0) 2 (10.0) 3 (3.7)
Other 0 (0.0) 4 (20.0) 2 (10.0) 1 (5.0) 7 (8.6)
Prefer not to say 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 1 (1.2)
Ethnicity
English/Welsh/Scottish 8 (40.0) 9 (45.0) 12 (57.0) 8 (40.0) 37 (45.7)
Any other white
background 4 (20.0) 0 (0.0) 0 (0.0) 2 (10.0) 6 (7.4)
White and black
Caribbean 0 (0.0) 1 (5.0) 0 (0.0) 2 (10.0) 3 (3.7)
White and Asian 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 1 (1.2)
Other mixed 0 (0.0) 0 (0.0) 2 (9.0) 0 (0.0) 2 (2.6)
Indian 1 (5.0) 3 (15.0) 1 (5.0) 0 (0.0) 5 (6.2)
Pakistani 0 (0.0) 2 (10.0) 3 (14.0) 3 (15.0) 8 (9.9)
Bangladeshi 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 1 (1.2)
Chinese 2 (10.0) 1 (5.0) 0 (0.0) 0 (0.0) 3 (3.7)
Other Asian
background 2 (10.0) 0 (0.0) 1 (5.0) 0 (0.0) 3 (3.7)
African 1 (5.0) 2 (10.0) 1 (5.0) 2 (10.0) 6 (7.4)
Caribbean 1 (5.0) 1 (5.0) 0 (0.0) 2 (10.0) 4 (4.9)
Other ethnic group 1 (5.0) 0 (0.0) 0 (0.0) 1 (5.0) 2 (2.5)
Forty participants received a scenario (2,4) where the sensor was attached to the
packaging and 41 received a scenario (3,4) which informed them that a pharmacist had
completed visual checks on the product.
2.6. Qualitative Analysis
The qualitative comments left on the questionnaires were also analysed using the-
matic analysis [24]. This approach was used because it provided a way of organising the
qualitative data in the form of themes: recurrent topics, ideas or statements identified
across the corpus of data. The comments were analysed manually by YL in consultation
with PD, according to the six phases described by Braun and Clarke [24]. The process
involved familiarisation with the data, coding, searching for themes, reviewing themes,
defining and naming themes, and writing up. After familiarisation with the data, YL
coded each comment and assigned initial ‘code names’. The codes were then grouped
together under common themes and the themes in turn were grouped according to two
higher-order categories.
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3. Results
In terms of people’s ‘attitude’ toward the medication, the F ratios were calculated
to be as follows; for the effect of the presence of the ‘sensor’, F (1, 77) = 7.09, p < 0.01,
the provision of information about visual-checking by the ‘pharmacist’, F (1, 77) = 9.63,
p < 0.005, and the interaction between sensor and pharmacist, F (1, 77) = 0.001, p = 0.974
(see Figure 3).
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and, eparately, the stimated marginal means plotted against e ch other to show any interaction (none in this i sta ce).
In terms of people’s ‘intention’ to accept the medication, the F ratios were calculated
to be as follows; for the effect of the presence of the ‘sensor’, F (1, 77) = 5.21, p < 0.05
the provision of information about visual-checking by the ‘pharmacist’, F (1, 77) = 10.71,
p < 0.005, and the interaction between sensor and pharmacist, F (1, 77) = 0.018, p = 0.903
(see Figure 5).
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3.1. Qualitative Comments
The two super-ordinate categories identified are shown below along with their themes.
3.2. Participants’ Expectations of Medicines Reuse
The four themes within this category relate to people’s expectations of medicines reuse.
3.2.1. Physical Characteristics of Re-Dispensed Medicines
Regardless of the scenario, participants wondered whether the medication packaging
had been previously opened and wanted factors such as anti-tampering stickers and phar-
macist checks to improv their confidence about the authenticity of any reused medication.
For example:
• “If you told me it’s been unopened and you can tell by the antitampering sticker, it is
fine to take.” (45–54-year-old male, Scenario 1)
• “If tampered then I would give more uncertainty but if checks are in place and come
back fine, I would have no issue. (18–24-year-old female, Scenario 4)
3.2.2. Process of Checking for Quality
Participants in Scenarios 3 and 4 were told that a pharmacist had checked the medica-
tion for quality and safety. Many thought that a pharmacist was the right professional to
be trusted to perform quality and safety checks of returned medicines. Moreover, for some
participants in Scenario 4, the presence of a sensor was thought to enhance the pharmacist’s
ability to confirm the safety of the medicine. For example:
• It is safe to take as long as pharmacist has checked it (18–24-year-old female, Scenario 3).
• Happier to receive re-used medication that contains a sensor than without due to it
aiding the pharmacist with their safety checks. (18–24-year-old male, Scenario 4).
3.2.3. Logistics of Medicines Reuse
In Scenarios 3 and 4, some participants were concerned about the potential burden
on pharmacists performing the quality and safety checks of returned medicines due to the
additional workload that would be involved. A number of participants in Scenario 3 were
uncertain about effectiveness of the checks performed by the pharmacist. For example:
• In theory would reduce medicines wastage however safety cannot be guaranteed
even with checks and would be an extra workload on community pharmacists.
(25–34-year-old female, Scenario 3).
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3.2.4. Incentives to Engage in Medicines Reuse
A number of participants would only engage in medicines reuse under specific condi-
tions. For example:
• I would only take it if there was an incentive e.g., no others available and if it was
cheaper/free of charge. (18–24-year-old male, Scenario 1).
• If I was in desperate need of the medication, I would believe that it was safe for me.
But I would still be a little cautious when taking it. People can open and re-seal.
(18–24-year-old female, Scenario 4).
3.3. Understanding the Consequences of Medicines Reuse
3.3.1. Potential Disadvantages of Re-Dispensing Medicines
Some participants expressed uncertainties over the quality and safety of medicines,
once handled by other people. Further, some expressed that re-dispensed medicines could
be unsafe due to contamination. For example:
• I don not trust where a stranger has put the box. It could change the medication
quality. (18–24-year-old, female, Scenario 1).
• I do not like the idea of someone else other than a healthcare practitioner being in
handle of my medication. (18–24-year-old female, Scenario 2).
• The packaging could be infected with unidentified bacteria, so taking a risk could be
potentially dangerous. (18–24-year-old, Scenario 3).
3.3.2. Potential Advantages of Medicines Reuse
Some participants also mentioned the economic and environmental benefits of reusing
medicines. Several participants stated that medicines reuse could aid the NHS in minimiz-
ing costs. For example:
• I think if it’s safe and good to use and it would help reduce cost to the NHS.
(35–44-year-old female, Scenario 4).
• I think this is a very good idea and will stop wasting the medication. (55–64-year-old
female, Scenario 3).
• Re-using unopened medication is a good idea. It could help prevent a shortage of
specific medications that are needed. (18–24-year-old female, Scenario 4).
4. Discussion
As hypothesized, participants gave more positive responses to questions about
medicines reuse with the presence of the sensor on the packaging compared to with-
out. This was across all three domains of attitude toward the medication, social pressure
to accept it, and intention to do so. Participants also gave more favourable responses on
hearing about the pharmacist’s involvement in the visual checking of the medication com-
pared to without. What-is-more, consistently, the inclusion of the sensor on the packaging
resulted in better (more pro-medicines-reuse) responses compared to the visual-checking
statement, with the inclusion of both conditions giving the highest scores across attitude
toward the medication, social pressure to accept it, and intention to do so. The study
provides important evidence about the potential for sensors that measure and track the
interaction of the storage conditions with the medicinal pack to reassure people about
medicines reuse and encourage them to engage with such a scheme in the future should
this be sanctioned by regulators.
A strength of this study is the use of the experimental method. Experiments allow
researchers to manipulate the independent variables so that causal inference can be made in
terms of the desired outcomes. Thus, through the design of our experiment, we were able
to introduce the phenomenon of a sensor and visual-checking information in a controlled
manner and then study the impact on people’s pro-medicines-reuse beliefs. This provides
a good degree of confidence about the cause-effect of the relationships that we were
investigating. A potential weakness is that our participants’ age and education were not
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representative of the general population or a hypothesized ‘average’ pharmacy customer.
While education levels could influence decisions, the likely impact of age on risky decisions
is less clear [25]. In addition, because of capacity constraints, each of the four scenarios
was tested with only 20 people. Nonetheless, because of the large effect sizes between
the different conditions, the study was evidently sufficiently powered to illustrate the
statistically significant differences in the outcome measures. Another strength of the study
is the accompanying qualitative analysis which provided added explanation to bolster
the findings.
The comments from the questionnaire related either to people’s expectations about
medicines reuse or illustrated their understanding of the consequences of medicines reuse.
In this way, the qualitative comments helped validate the main findings as the participants
explained their concerns about the quality of re-dispensed medicines and highlighted
how a sensor as well as the involvement of the pharmacist might help increase their
confidence in such a product. The comments made by the participants also aligned well
with other ideas about medicines reuse found in research elsewhere [1,3,4], for example
its role in waste prevention, medicines shortages, its potential impact on pharmacist time
and the idea of patient incentives to engage with the practice. One of the most significant
outcomes of the current study, however, is the findings that the presence of sensors has
a greater impact on people’s pro-medicines reuse beliefs compared with the provision of
information about pharmacist checks. Although it makes logical sense to trust technology
that can provide objective proof about the storage conditions of medication, over and
above the visual checks that a pharmacist might provide, this study adds evidence to the
ideas proposed in our ReMINDS ecosystem as a publicly-acceptable solution for reusing
returned, prescribed medicines [18,19]. This system relies on active sensing technologies
on packaging, integrated with the Internet of Things platform to validate the quality and
safety of the medicines while interconnecting the relevant stakeholders [11,12].
Smart packaging concepts are new to medication packs but have been around in the
food industry for a number of years [26]. This is not to deny the other sophisticated features
of pharmaceutical packaging, which is advanced and well researched [27]. However, the
use of technology to enable reuse of medicines is not common and the corresponding
research is not at all mainstream [18]. It is important to highlight that smart packaging
in that industry consists of more than temperature/humidity sensors, extending to such
things as integrity indicators, freshness indicators, and even radiofrequency identification
(RFID) tags to identify and locate the product [28]. The current paper only tested the idea
of one type of sensor, in a small experiment. Another learning point from the food industry
is to consider the environmental impact of the packaging itself against the potential for it to
reduce product waste [29]. Therefore, the attachment of sensor technology to medication
packaging will not necessarily solve the overall problem of waste created by medication,
unless shown to be carbon neutral. While the current paper makes a small contribution to
understanding the public’s attitude towards medicines reuse, research on smart packaging
within the food industry also offers a wealth of more nuanced information about the impact
of such technology on consumer perceptions [30]. For example, a recent review in the food
industry unearths not only the functional value of smart packaging (e.g., protecting the
content) but also communication value (e.g., perception of safer product), social value (e.g.,
societal trends towards sustainable living), emotional value (e.g., feeling more confident
about the product), and so on [30]. There can also be barriers to the use of smart packaging,
such as value barrier (e.g., increased price of final product) and tradition barrier (e.g.,
getting used to a new type of behavior) discussed in detail elsewhere [30].
It is worth noting that the sensors attached to the medication box (Timestrip® Plus
sticker and a downsized version of an SCS humidity indicator) used in the experiments
were non-functioning and used for theoretical purposes only in order to mimic the monitor-
ing of temperature and humidity, respectively. More investigations should be undertaken
in the future with appropriate indicators, specifically designed to function for medicines
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reuse schemes. These studies could probe consumer responses in more detail, to examine
other potential values and barriers to the use of smart packaging for medication packs.
5. Conclusions
This study suggests that the addition of sensors to the packaging of medicines com-
bined with visual quality and safety checks carried out by pharmacists create a more
positive response about medicines reuse, compared to their absence. The use of sensors
on medication packaging forms the basis of our proposed ReMINDS ecosystem, which
warrants further investigation.
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